APO-DORZOLAMIDE SOLUTION

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE)

থেকে পাওয়া:

APOTEX INC

এটিসি কোড:

S01EC03

INN (আন্তর্জাতিক নাম):

DORZOLAMIDE

ডোজ:

2%

ফার্মাসিউটিকাল ফর্ম:

SOLUTION

রচনা:

DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 2%

প্রশাসন রুট:

OPHTHALMIC

প্যাকেজ ইউনিট:

100

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

CARBONIC ANHYDRASE INHIBITORS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0128558001; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2010-10-25

পণ্য বৈশিষ্ট্য

PRODUCT MONOGRAPH
APO-DORZOLAMIDE
DORZOLAMIDE HYDROCHLORIDE OPHTHALMIC SOLUTION
DORZOLAMIDE 2% WEIGHT/VOLUME
STERILE OPHTHALMIC SOLUTION
ELEVATED INTRAOCULAR PRESSURE THERAPY
(TOPICAL CARBONIC ANHYDRASE INHIBITOR)
APOTEX INC.
DATE OF PREPARATION:
150 SIGNET DRIVE
OCTOBER 25, 2010
TORONTO, ONTARIO
M9L 1T9
CONTROL NUMBER:
107589, 141578
_____________________________________________________________________________________________
_APO-DORZOLAMIDE Product Monograph _
_ _
_Page 2 of 20_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..........................................
3
SUMMARY PRODUCT
INFORMATION.........................................................
3
INDICATIONS AND CLINICAL
USE...............................................................
3
CONTRAINDICATIONS
....................................................................................
3
WARNINGS AND
PRECAUTIONS...................................................................
4
ADVERSE REACTIONS
....................................................................................
6
DRUG
INTERACTIONS.....................................................................................
7
DOSAGE AND
ADMINISTRATION.................................................................
8
OVERDOSAGE
...................................................................................................
8
ACTION AND CLINICAL PHARMACOLOGY
...............................................
9
STORAGE AND
STABILITY.............................................................................
10
DOSAGE FORMS, COMPOSITION AND
PACKAGING................................
10
PART II: SCIENTIFIC INFORMATION
..................................................................
11
PHARMACEUTICAL INFORMATION
............................................................
11
CLINICAL
TRIALS.............................................................................................
11
DETAILED
PHARMACOLOGY........................................................................
13
T